Genfa Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Genfa Xiao has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Liangdi Xie
Department of Geriatrics, Fujian Hypertension Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
4 shared publications Xiaoli Liu
Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, First Affiliated Hospital of Gannan Medical University
3 shared publicationsGuili Lian
Department of Geriatrics, First Affiliated Hospital of Fujian Medical University
2 shared publications- Guili Lian
Department of Geriatrics, The First Affiliated Hospital of Fujian Medical University, China
2 shared publications Haobo Wang
First Clinical Medical College of Gannan Medical University
2 shared publicationsHuajun Wang
Fujian Hypertension Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1863052
ADAMTS4 is a serum biomarker for pulmonary arterial hypertension associated with congenital heart disease
Objectives: Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a cardiopulmonary disorder characterized by pathological pulmonary vascular remodeling and perivascular inflammatory cell infiltration. ADAMTS4 is a secreted, zinc-dependent metalloprotease critically involved in extracellular matrix degradation and turnover and has recently emerged as a potential biomarker in vascular remodeling diseases. This study aimed to evaluate the diagnostic performance and prognostic value of serum ADAMTS4 in patients with PAH-CHD. Methods: This study included patients with PAH-CHD, patients with CHD, and healthy controls. Serum ADAMTS4 levels were measured by ELISA. Correlations with clinical parameters were assessed using Spearman’s rank correlation. The diagnostic efficacy was evaluated by ROC curve analysis. Univariate and multivariable logistic regression were used to identify independent risk factors associated with the presence of PAH-CHD. PAH-CHD patients were followed up for a median duration of 40.5 months, and Kaplan–Meier and Cox regression analyses were used to analyze prognosis. Results: Compared with those in CHD patients and healthy controls, serum ADAMTS4 levels were elevated in PAH-CHD patients. ADAMTS4 was positively correlated with NT-proBNP ( r = 0.45, p = 0.002), CRP ( r = 0.60, p < 0.001), and WHO functional class ( r = 0.49, p < 0.001). ROC analysis demonstrated good discriminatory ability for differentiating PAH-CHD from CHD (AUC = 0.78; 95% CI: 0.69–0.87; p < 0.001), with an optimal cutoff value of 42.2 ng/mL. After multivariable adjustment, logistic regression revealed that ADAMTS4 remained an independent factor associated with the presence of PAH-CHD (OR = 1.189; 95% CI: 1.036–1.365; p = 0.014). Kaplan–Meier analysis revealed significantly shorter event-free survival in patients with ≥ 42.2 ng/mL ADAMTS4 than in those with lower levels (log-rank p = 0.046). After multivariable adjustment, Cox regression confirmed ADAMTS4 as an independent predictor of adverse clinical events (HR = 1.038; 95% CI: 1.007–1.071; p = 0.017). Conclusion: Serum ADAMTS4 is elevated in patients with PAH-CHD and is correlated with disease severity and adverse outcomes. These findings support its utility as a noninvasive serum biomarker for diagnosis, risk stratification and prognostic assessment in PAH-CHD patients.
- 22 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1863052
Open AccessADAMTS4 is a serum biomarker for pulmonary arterial hypertension associated with congenital heart disease
Objectives: Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a cardiopulmonary disorder characterized by pathological pulmonary vascular remodeling and perivascular inflammatory cell infiltration. ADAMTS4 is a secreted, zinc-dependent metalloprotease critically involved in extracellular matrix degradation and turnover and has recently emerged as a potential biomarker in vascular remodeling diseases. This study aimed to evaluate the diagnostic performance and prognostic value of serum ADAMTS4 in patients with PAH-CHD. Methods: This study included patients with PAH-CHD, patients with CHD, and healthy controls. Serum ADAMTS4 levels were measured by ELISA. Correlations with clinical parameters were assessed using Spearman’s rank correlation. The diagnostic efficacy was evaluated by ROC curve analysis. Univariate and multivariable logistic regression were used to identify independent risk factors associated with the presence of PAH-CHD. PAH-CHD patients were followed up for a median duration of 40.5 months, and Kaplan–Meier and Cox regression analyses were used to analyze prognosis. Results: Compared with those in CHD patients and healthy controls, serum ADAMTS4 levels were elevated in PAH-CHD patients. ADAMTS4 was positively correlated with NT-proBNP ( r = 0.45, p = 0.002), CRP ( r = 0.60, p < 0.001), and WHO functional class ( r = 0.49, p < 0.001). ROC analysis demonstrated good discriminatory ability for differentiating PAH-CHD from CHD (AUC = 0.78; 95% CI: 0.69–0.87; p < 0.001), with an optimal cutoff value of 42.2 ng/mL. After multivariable adjustment, logistic regression revealed that ADAMTS4 remained an independent factor associated with the presence of PAH-CHD (OR = 1.189; 95% CI: 1.036–1.365; p = 0.014). Kaplan–Meier analysis revealed significantly shorter event-free survival in patients with ≥ 42.2 ng/mL ADAMTS4 than in those with lower levels (log-rank p = 0.046). After multivariable adjustment, Cox regression confirmed ADAMTS4 as an independent predictor of adverse clinical events (HR = 1.038; 95% CI: 1.007–1.071; p = 0.017). Conclusion: Serum ADAMTS4 is elevated in patients with PAH-CHD and is correlated with disease severity and adverse outcomes. These findings support its utility as a noninvasive serum biomarker for diagnosis, risk stratification and prognostic assessment in PAH-CHD patients.
- Open Access
- 21 May 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1763556
Defect in lysosomal enzyme trafficking and sorting is associated with irreversibility of pulmonary arterial hypertension
Background: Patients with congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) have a reversible stage, during which shunt closure reverses PAH. However, PAH is irreversible beyond a certain time point, and the molecular mechanisms underlying the switch from reversible to irreversible PAH remain poorly understood. Methods: Three transcriptomic datasets were obtained from the Gene Expression Omnibus database. Weighted gene co-expression network analysis (WGCNA) was performed to identify gene modules significantly associated with PAH irreversibility. Serum samples were collected from 40 patients with CHD-PAH, 20 patients with congenital heart disease (CHD), and 20 healthy controls. Protein levels in serum were quantified using enzyme-linked immunosorbent assay. Results: WGCNA generated 16 gene modules, and one of the modules showing the highest positive correlation with PAH irreversibility was recognized as the key module. GO and KEGG pathway analyses of key module revealed that PAH irreversibility was associated with lysosome. Pathview analysis indicated dysfunctional lysosome in irreversible PAH, including dysregulation of lysosomal enzymes and impaired lysosomal transport and acidification. Comprehensive characterization of lysosome identified a set of downregulated genes, including Gnptab, M6pr, and Arf1, whose expression patterns shifted significantly during the transition from reversible to irreversible PAH. Functional enrichment analysis linked these genes to lysosomal enzyme trafficking and sorting. The downregulation of M6PR, a receptor involved in lysosomal trafficking and sorting, was validated using independent datasets and clinical samples. Additionally, eight lysosomal hub genes were identified, including Ctsd, Ctsk, Ctsb, Ctsa, Pld3, Tpsab1, Lgals3 and Smpdl3a; among them, serum protein levels of CTSD, CTSB, and LGALS3 were significantly elevated in CHD patients with irreversible PAH compared to those with reversible PAH. Conclusion: This study identified dysfunctional lysosome in irreversible PAH, and the loss of compensation for lysosomal trafficking and sorting may be associated with a switch from reversible to irreversible PAH, thus providing novel insights into the molecular mechanisms underlying irreversible PAH.
- 21 May 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1763556
Open AccessDefect in lysosomal enzyme trafficking and sorting is associated with irreversibility of pulmonary arterial hypertension
Background: Patients with congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) have a reversible stage, during which shunt closure reverses PAH. However, PAH is irreversible beyond a certain time point, and the molecular mechanisms underlying the switch from reversible to irreversible PAH remain poorly understood. Methods: Three transcriptomic datasets were obtained from the Gene Expression Omnibus database. Weighted gene co-expression network analysis (WGCNA) was performed to identify gene modules significantly associated with PAH irreversibility. Serum samples were collected from 40 patients with CHD-PAH, 20 patients with congenital heart disease (CHD), and 20 healthy controls. Protein levels in serum were quantified using enzyme-linked immunosorbent assay. Results: WGCNA generated 16 gene modules, and one of the modules showing the highest positive correlation with PAH irreversibility was recognized as the key module. GO and KEGG pathway analyses of key module revealed that PAH irreversibility was associated with lysosome. Pathview analysis indicated dysfunctional lysosome in irreversible PAH, including dysregulation of lysosomal enzymes and impaired lysosomal transport and acidification. Comprehensive characterization of lysosome identified a set of downregulated genes, including Gnptab, M6pr, and Arf1, whose expression patterns shifted significantly during the transition from reversible to irreversible PAH. Functional enrichment analysis linked these genes to lysosomal enzyme trafficking and sorting. The downregulation of M6PR, a receptor involved in lysosomal trafficking and sorting, was validated using independent datasets and clinical samples. Additionally, eight lysosomal hub genes were identified, including Ctsd, Ctsk, Ctsb, Ctsa, Pld3, Tpsab1, Lgals3 and Smpdl3a; among them, serum protein levels of CTSD, CTSB, and LGALS3 were significantly elevated in CHD patients with irreversible PAH compared to those with reversible PAH. Conclusion: This study identified dysfunctional lysosome in irreversible PAH, and the loss of compensation for lysosomal trafficking and sorting may be associated with a switch from reversible to irreversible PAH, thus providing novel insights into the molecular mechanisms underlying irreversible PAH.
- Open Access
The landscape of coagulation cascade in pulmonary arterial hypertension
Background: Both the thrombotic and bleeding events were frequently complicated in pulmonary arterial hypertension (PAH), making recommendations regarding anticoagulation difficult. Methods: The histopathological examination was performed on the lungs of two PAH models and global coagulation cascade alteration in lung tissue and peripheral venous blood was assessed by RNA sequencing and immunoassay, respectively. The clinical data and plasma samples were collected from PAH patients and controls and plasma coagulation cascade in subject was quantified by both immunoassay and proteomic approach. Results: RNA sequencing analysis of lung tissues in two PAH models showed the reduced anticoagulants and intrinsic clotting factors and increased tissue factor (TF) expression. The immunoassay assessment of coagulation cascade in PAH models revealed increased TF expression, reduced intrinsic and common clotting factors and decreased anticoagulants antithrombin (AT)-Ⅲ in the peripheral circulation. Additionally, clinical evaluation of hemostatic parameters in PAH patients demonstrated hemostatic deficiency and lower AT-Ⅲ activity. Consistently, proteomic and immunoassay analysis of coagulation cascade in PAH patients revealed the increased extrinsic clotting factors, impairment of intrinsic and common pathways and impairment of AT-Ⅲ anticoagulant pathway. Conclusions: The activation of extrinsic pathway and impairment of heparin/AT-Ⅲ anticoagulant system are conserved mechanisms for thrombosis across rat and human PAH, restoring its function with heparin supplementation may be a better option for future anticoagulant therapy. Clinical Perspective: What Is New? The activation of extrinsic pathway and impairment of heparin/AT-Ⅲ system were responsible for thrombosis in pulmonary arterial hypertension. Impairment of intrinsic and common pathways, due to reduced plasma levels of clotting factors F10, F11, F2 and vWF, contributed to hemorrhagic complications, such as hemoptysis in PAH patients. What Are the Clinical Implications? Increased risk of bleeding for anticoagulation with warfarin and novel oral anticoagulants may be attributed to further impairment of intrinsic and common pathways in PAH. Restoring function of heparin/ AT-Ⅲ anticoagulant system with heparin supplementation may be a better option for future anticoagulant therapy.
Open AccessThe landscape of coagulation cascade in pulmonary arterial hypertension
Background: Both the thrombotic and bleeding events were frequently complicated in pulmonary arterial hypertension (PAH), making recommendations regarding anticoagulation difficult. Methods: The histopathological examination was performed on the lungs of two PAH models and global coagulation cascade alteration in lung tissue and peripheral venous blood was assessed by RNA sequencing and immunoassay, respectively. The clinical data and plasma samples were collected from PAH patients and controls and plasma coagulation cascade in subject was quantified by both immunoassay and proteomic approach. Results: RNA sequencing analysis of lung tissues in two PAH models showed the reduced anticoagulants and intrinsic clotting factors and increased tissue factor (TF) expression. The immunoassay assessment of coagulation cascade in PAH models revealed increased TF expression, reduced intrinsic and common clotting factors and decreased anticoagulants antithrombin (AT)-Ⅲ in the peripheral circulation. Additionally, clinical evaluation of hemostatic parameters in PAH patients demonstrated hemostatic deficiency and lower AT-Ⅲ activity. Consistently, proteomic and immunoassay analysis of coagulation cascade in PAH patients revealed the increased extrinsic clotting factors, impairment of intrinsic and common pathways and impairment of AT-Ⅲ anticoagulant pathway. Conclusions: The activation of extrinsic pathway and impairment of heparin/AT-Ⅲ anticoagulant system are conserved mechanisms for thrombosis across rat and human PAH, restoring its function with heparin supplementation may be a better option for future anticoagulant therapy. Clinical Perspective: What Is New? The activation of extrinsic pathway and impairment of heparin/AT-Ⅲ system were responsible for thrombosis in pulmonary arterial hypertension. Impairment of intrinsic and common pathways, due to reduced plasma levels of clotting factors F10, F11, F2 and vWF, contributed to hemorrhagic complications, such as hemoptysis in PAH patients. What Are the Clinical Implications? Increased risk of bleeding for anticoagulation with warfarin and novel oral anticoagulants may be attributed to further impairment of intrinsic and common pathways in PAH. Restoring function of heparin/ AT-Ⅲ anticoagulant system with heparin supplementation may be a better option for future anticoagulant therapy.
- Open Access
- 6 October 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 909399
Weighted gene co-expression network analysis identifies dysregulated B-cell receptor signaling pathway and novel genes in pulmonary arterial hypertension
Background: Pulmonary arterial hypertension (PAH) is a devastating cardio-pulmonary vascular disease in which chronic elevated pulmonary arterial pressure and pulmonary vascular remodeling lead to right ventricular failure and premature death. However, the exact molecular mechanism causing PAH remains unclear.Methods: RNA sequencing was used to analyze the transcriptional profiling of controls and rats treated with monocrotaline (MCT) for 1, 2, 3, and 4 weeks. Weighted gene co-expression network analysis (WGCNA) was employed to identify the key modules associated with the severity of PAH. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to explore the potential biological processes and pathways of key modules. Real-time PCR and western blot analysis were used to validate the gene expression. The hub genes were validated by an independent dataset obtained from the Gene Expression Omnibus database.Results: A total of 26 gene modules were identified by WGCNA. Of these modules, two modules showed the highest correlation with the severity of PAH and were recognized as the key modules. GO analysis of key modules showed the dysregulated inflammation and immunity, particularly B-cell-mediated humoral immunity in MCT-induced PAH. KEGG pathway analysis showed the significant enrichment of the B-cell receptor signaling pathway in the key modules. Pathview analysis revealed the dysregulation of the B-cell receptor signaling pathway in detail. Moreover, a series of humoral immune response-associated genes, such as BTK, BAFFR, and TNFSF4, were found to be differentially expressed in PAH. Additionally, five genes, including BANK1, FOXF1, TLE1, CLEC4A1, and CLEC4A3, were identified and validated as the hub genes.Conclusion: This study identified the dysregulated B-cell receptor signaling pathway, as well as novel genes associated with humoral immune response in MCT-induced PAH, thereby providing a novel insight into the molecular mechanisms underlying inflammation and immunity and therapeutic targets for PAH.
- 6 October 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 909399
Open AccessWeighted gene co-expression network analysis identifies dysregulated B-cell receptor signaling pathway and novel genes in pulmonary arterial hypertension
Background: Pulmonary arterial hypertension (PAH) is a devastating cardio-pulmonary vascular disease in which chronic elevated pulmonary arterial pressure and pulmonary vascular remodeling lead to right ventricular failure and premature death. However, the exact molecular mechanism causing PAH remains unclear.Methods: RNA sequencing was used to analyze the transcriptional profiling of controls and rats treated with monocrotaline (MCT) for 1, 2, 3, and 4 weeks. Weighted gene co-expression network analysis (WGCNA) was employed to identify the key modules associated with the severity of PAH. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to explore the potential biological processes and pathways of key modules. Real-time PCR and western blot analysis were used to validate the gene expression. The hub genes were validated by an independent dataset obtained from the Gene Expression Omnibus database.Results: A total of 26 gene modules were identified by WGCNA. Of these modules, two modules showed the highest correlation with the severity of PAH and were recognized as the key modules. GO analysis of key modules showed the dysregulated inflammation and immunity, particularly B-cell-mediated humoral immunity in MCT-induced PAH. KEGG pathway analysis showed the significant enrichment of the B-cell receptor signaling pathway in the key modules. Pathview analysis revealed the dysregulation of the B-cell receptor signaling pathway in detail. Moreover, a series of humoral immune response-associated genes, such as BTK, BAFFR, and TNFSF4, were found to be differentially expressed in PAH. Additionally, five genes, including BANK1, FOXF1, TLE1, CLEC4A1, and CLEC4A3, were identified and validated as the hub genes.Conclusion: This study identified the dysregulated B-cell receptor signaling pathway, as well as novel genes associated with humoral immune response in MCT-induced PAH, thereby providing a novel insight into the molecular mechanisms underlying inflammation and immunity and therapeutic targets for PAH.
- Open Access
- 11 October 2021
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 19 (1) , 1-16
Zinc-mediated activation of CREB pathway in proliferation of pulmonary artery smooth muscle cells in pulmonary hypertension
Background: Transcription factor CREB is involved in the development of pulmonary hypertension (PH). However, little is known about the role and regulatory signaling of CREB in PH. Methods: A series of techniques, including bioinformatics methods, western blot, cell proliferation and luciferase reporter assay were used to perform a comprehensive analysis of the role and regulation of CREB in proliferation of pulmonary artery smooth muscle cells (PASMCs) in PH. Results: Using bioinformatic analysis of the differentially expressed genes (DEGs) identified in the development of monocrotaline (MCT)- and hypoxia-induced PH, we found the overrepresentation of CRE-containing DEGs. Western blot analysis revealed a sustained increase in total- and phosphorylated-CREB in PASMCs isolated from rats treated with MCT. Similarly, an enhanced and prolonged serum-induced CREB phosphorylation was observed in hypoxia-pretreated PASMCs. The sustained CREB phosphorylation in PASMCs may be associated with multiple protein kinases phosphorylated CREB. Additionally, hierarchical clustering analysis showed reduced expression of the majority of CREB phosphatases in PH, including regulatory subunits of PP2A, Ppp2r2c and Ppp2r3a. Cell proliferation analysis showed increased PASMCs proliferation in MCT-induced PH, an effect relied on CREB-mediated transcriptional activity. Further analysis revealed the raised intracellular labile zinc possibly from ZIP12 was associated with reduced phosphatases, increased CREB-mediated transcriptional activity and PASMCs proliferation. Conclusions: CREB pathway was overactivated in the development of PH and contributed to PASMCs proliferation, which was associated with multiple protein kinases and/or reduced CREB phosphatases and raised intracellular zinc. Thus, this study may provide a novel insight into the CREB pathway in the pathogenesis of PH.
- 11 October 2021
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 19 (1) , 1-16
Open AccessZinc-mediated activation of CREB pathway in proliferation of pulmonary artery smooth muscle cells in pulmonary hypertension
Background: Transcription factor CREB is involved in the development of pulmonary hypertension (PH). However, little is known about the role and regulatory signaling of CREB in PH. Methods: A series of techniques, including bioinformatics methods, western blot, cell proliferation and luciferase reporter assay were used to perform a comprehensive analysis of the role and regulation of CREB in proliferation of pulmonary artery smooth muscle cells (PASMCs) in PH. Results: Using bioinformatic analysis of the differentially expressed genes (DEGs) identified in the development of monocrotaline (MCT)- and hypoxia-induced PH, we found the overrepresentation of CRE-containing DEGs. Western blot analysis revealed a sustained increase in total- and phosphorylated-CREB in PASMCs isolated from rats treated with MCT. Similarly, an enhanced and prolonged serum-induced CREB phosphorylation was observed in hypoxia-pretreated PASMCs. The sustained CREB phosphorylation in PASMCs may be associated with multiple protein kinases phosphorylated CREB. Additionally, hierarchical clustering analysis showed reduced expression of the majority of CREB phosphatases in PH, including regulatory subunits of PP2A, Ppp2r2c and Ppp2r3a. Cell proliferation analysis showed increased PASMCs proliferation in MCT-induced PH, an effect relied on CREB-mediated transcriptional activity. Further analysis revealed the raised intracellular labile zinc possibly from ZIP12 was associated with reduced phosphatases, increased CREB-mediated transcriptional activity and PASMCs proliferation. Conclusions: CREB pathway was overactivated in the development of PH and contributed to PASMCs proliferation, which was associated with multiple protein kinases and/or reduced CREB phosphatases and raised intracellular zinc. Thus, this study may provide a novel insight into the CREB pathway in the pathogenesis of PH.
- Open Access
- 29 August 2020
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (19) , 11409-11421
Transcriptomic analysis identifies Toll‐like and Nod‐like pathways and necroptosis in pulmonary arterial hypertension
Inflammation and immunity play a causal role in the pathogenesis of pulmonary vascular remodelling and pulmonary arterial hypertension (PAH). However, the pathways and mechanisms by which inflammation and immunity contribute to pulmonary vascular remodelling remain unknown. RNA sequencing was used to analyse the transcriptome in control and rats injected with monocrotaline (MCT) for various weeks. Using the transcriptional profiling of MCT‐induced PAH coupled with bioinformatics analysis, we clustered the differentially expressed genes (DEGs) and chose the increased expression patterns associated with inflammatory and immune response. We found the enrichment of Toll‐like receptor (TLR) and Nod‐like receptor (NLR) pathways and identified NF‐κB‐mediated inflammatory and immune profiling in MCT‐induced PAH. Pathway‐based data integration and visualization showed the dysregulated TLR and NLR pathways, including increased expression of TLR2 and NLRP3, and their downstream molecules. Further analysis revealed that the activation of TLR and NLR pathways was associated with up‐regulation of damage‐associated molecular patterns (DAMPs) and RIPK3‐mediated necroptosis was involved in the generation of DAMPs in MCT‐induced PAH. Collectively, we identify RIPK3‐mediated necroptosis and its triggered TLR and NLR pathways in the progression of pulmonary vascular remodelling, thus providing novel insights into the mechanisms underlying inflammation and immunity in the pathogenesis of PAH.
- 29 August 2020
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (19) , 11409-11421
Open AccessTranscriptomic analysis identifies Toll‐like and Nod‐like pathways and necroptosis in pulmonary arterial hypertension
Inflammation and immunity play a causal role in the pathogenesis of pulmonary vascular remodelling and pulmonary arterial hypertension (PAH). However, the pathways and mechanisms by which inflammation and immunity contribute to pulmonary vascular remodelling remain unknown. RNA sequencing was used to analyse the transcriptome in control and rats injected with monocrotaline (MCT) for various weeks. Using the transcriptional profiling of MCT‐induced PAH coupled with bioinformatics analysis, we clustered the differentially expressed genes (DEGs) and chose the increased expression patterns associated with inflammatory and immune response. We found the enrichment of Toll‐like receptor (TLR) and Nod‐like receptor (NLR) pathways and identified NF‐κB‐mediated inflammatory and immune profiling in MCT‐induced PAH. Pathway‐based data integration and visualization showed the dysregulated TLR and NLR pathways, including increased expression of TLR2 and NLRP3, and their downstream molecules. Further analysis revealed that the activation of TLR and NLR pathways was associated with up‐regulation of damage‐associated molecular patterns (DAMPs) and RIPK3‐mediated necroptosis was involved in the generation of DAMPs in MCT‐induced PAH. Collectively, we identify RIPK3‐mediated necroptosis and its triggered TLR and NLR pathways in the progression of pulmonary vascular remodelling, thus providing novel insights into the mechanisms underlying inflammation and immunity in the pathogenesis of PAH.
- Open Access
- 16 March 2020
- Published by Impact Journals, LLC in Aging
- Vol. 12 (6) , 4953-4969
RNA sequencing analysis of monocrotaline-induced PAH reveals dysregulated chemokine and neuroactive ligand receptor pathways
Pulmonary arterial hypertension (PAH) is a serious disease characterized by elevated pulmonary artery pressure, inflammatory cell infiltration and pulmonary vascular remodeling. However, little is known about the pathogenic mechanisms underlying the disease onset and progression. RNA sequencing (RNA-seq) was used to identify the transcriptional profiling in control and rats injected with monocrotaline (MCT) for 1, 2, 3 and 4 weeks. A total of 23200 transcripts and 280, 1342, 908 and 3155 differentially expressed genes (DEGs) were identified at the end of week 1, 2, 3 and 4, of which Svop was the common top 10 DEGs over the course of PAH progression. Functional enrichment analysis of DEGs showed inflammatory/immune response occurred in the early stage of PAH development. KEGG pathway enrichment analysis of DEGs showed that cytokine-cytokine receptor interaction and neuroactive ligand-receptor interaction were in the initiation and progression of PAH. Further analysis revealed impaired expression of cholinergic receptors, adrenergic receptors including alpha1, beta1 and beta2 receptor, and dysregulated expression of γ-aminobutyric acid receptors. In summary, the dysregulated inflammation/immunity and neuroactive ligand receptor signaling pathways may be involved in the onset and progression of PAH.
- 16 March 2020
- Published by Impact Journals, LLC in Aging
- Vol. 12 (6) , 4953-4969
Open AccessRNA sequencing analysis of monocrotaline-induced PAH reveals dysregulated chemokine and neuroactive ligand receptor pathways
Pulmonary arterial hypertension (PAH) is a serious disease characterized by elevated pulmonary artery pressure, inflammatory cell infiltration and pulmonary vascular remodeling. However, little is known about the pathogenic mechanisms underlying the disease onset and progression. RNA sequencing (RNA-seq) was used to identify the transcriptional profiling in control and rats injected with monocrotaline (MCT) for 1, 2, 3 and 4 weeks. A total of 23200 transcripts and 280, 1342, 908 and 3155 differentially expressed genes (DEGs) were identified at the end of week 1, 2, 3 and 4, of which Svop was the common top 10 DEGs over the course of PAH progression. Functional enrichment analysis of DEGs showed inflammatory/immune response occurred in the early stage of PAH development. KEGG pathway enrichment analysis of DEGs showed that cytokine-cytokine receptor interaction and neuroactive ligand-receptor interaction were in the initiation and progression of PAH. Further analysis revealed impaired expression of cholinergic receptors, adrenergic receptors including alpha1, beta1 and beta2 receptor, and dysregulated expression of γ-aminobutyric acid receptors. In summary, the dysregulated inflammation/immunity and neuroactive ligand receptor signaling pathways may be involved in the onset and progression of PAH.